Search

Search Constraints

You searched for: Author/Creator Kleijn, Huub Jan

Search Results

1. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. Issue 4 (2nd November 2020)

2. Early stage development of the glycine‐1 re‐uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men. (20th May 2013)

3. Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment. Issue 3 (16th January 2020)

4. O4–05–05: Consistency of BACE inhibitor‐mediated brain amyloid production inhibition by MK‐8931 in Alzheimer's disease patients and healthy young adults. (1st July 2013)

5. P1‐038: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM EPOCH: A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE. (1st July 2006)

6. P1‐044: VERUBECESTAT DISEASE PROGRESSION MODELING FROM APECS, A PHASE 3 TRIAL IN PRODROMAL ALZHEIMER'S DISEASE: NO DOSE‐ AND EXPOSURE‐DEPENDENCY IN CLINICAL ENDPOINTS. (1st July 2019)

8. P1–361: Improved interpretation of amyloid tracer kinetic data through model‐based analysis. (1st July 2013)

9. P2‐002: AN INTEGRATED MECHANISTIC AMYLOID PATHWAY MODEL INFORMED BY CLINICAL BIOMARKER DATA FROM VERUBECESTAT AND OTHER BACE INHIBITORS. (1st July 2019)